Enter Crypto Patel, the man who’s seen more trendlines than actual trends, announcing that SOL has bounced off $130 like it remembered it left its dignity there. Apparently, this level isn’t just any number-it’s a magic confluence: horizontal support, rising trendline, ancient tribal markings from the Mayans (I may have made that last one up). But sure, let’s treat it like gospel.
SARB explained that, yes, a CBDC is technically feasible-much like training a penguin to commute by bus-but for the moment, they’d rather focus on the far less glamorous task of modernizing the payments system. Apparently, this must come first. Priorities, people.
Whales are accumulating like it’s a Black Friday sale, and the Futures Taker CVD is all like, “Yeah, let’s do this!” If the buy-side pressure holds, VIRTUAL might just keep dancing. 💃🕺
Oh, how the price of Ethereum has tried to claw its way from the depths! It began its rise above $2,880, much like the valiant hero in some forgotten epic, and now it seeks to stake its claim above the $2,920 and $2,950 levels.
The World Federation of Exchanges (WFE). Basically, the grown-ups. You know, Nasdaq, Deutsche Börse… the places where actual, regulated stock trading happens. Not a Discord server.
The SEC filing told us that the fund dumped its entire slice of MoonLake. All 313,571 shares, gone without a trace. That position had made up about 2.6% of their total assets-a decent chunk, yes, but a drop in the cosmic ocean of investment risk. They weren’t just throwing away money; they were preserving what little remained. The average quarterly prices turned that stake into a lamentable $14.8 million-a tidy sum for a company that seemed to be holding onto faint hopes and fragile promises.
BlackRock, that bastion of financial prudence, has, with a wave of its hand, dismissed the notion of an imminent XRP ETF filing. Mitchnick, ever the diplomat, attributes this to client demand not yet crossing the firm’s internal threshold. How quaint! Yet, one cannot help but wonder if this is merely a polite fiction, a veil draped over more strategic considerations. 🧐💼
Highlights of the madness:
To understand the move, we need to briefly wander into the territory of MPM BioImpact’s quarterly filings-a necessary evil for any fund that wishes to remain on the radar of the Securities and Exchange Commission. In their November 14 submission, it was revealed that MPM BioImpact sold every last one of its shares in Crinetics Pharmaceuticals. The $12.3 million value attributed to this transaction was calculated based on quarterly average prices, a standard practice in the world of investing. The fund’s holdings in Crinetics represented 2.1% of their assets under management (AUM) in the previous quarter. No small feat, though perhaps not enough to alter the course of history.
Enter the Chainlink reserve-think of it as the hoarder’s secret stash, but instead of old newspapers, it’s accumulating LINK. Why now? Why so aggressive? Is this the crypto version of “trust, but verify,” or just some fancy marketing trick? The latest reserve data might just hold the key to what’s really brewing beneath the surface-and hint at a rally that’s more than just hot air.
